Reiterating revenue guidance, especially in the biopharmaceutical sector, is a positive signal to investors about the company's performance and market confidence. This announcement is likely to instill investor confidence in Aurinia's business strategy and operational execution, potentially leading to a positive short-term impact on the stock price.